FDA finalises guidance on safety data for new dietary-supplement ingredients

The Food and Drug Administration has issued a final guidance describing the identity and safety information companies should submit when they notify the agency of a new dietary ingredient in a supplement. The agency announced the guidance's availability in the Federal Register on 20 October 2026 [s1]. It settles a narrow but long-running piece of supplement regulation that had sat in draft form for roughly a decade.

A new dietary ingredient, or NDI, is broadly an ingredient intended for use in a dietary supplement that was not marketed in the United States before the Dietary Supplement Health and Education Act took effect. For many such ingredients, a manufacturer or distributor must send the FDA a new dietary ingredient notification, or NDIN, with information supporting the conclusion that the supplement will reasonably be expected to be safe, before the product reaches the market. The new guidance addresses what that safety information should look like.

A decade in draft

The document finalises recommendations the FDA first floated years earlier. The agency published a draft guidance on NDI notifications on 5 July 2011 (76 FR 39111), took comment, and then issued a revised draft on 12 August 2016 (81 FR 53486), with the comment period later extended to 12 December 2016 (81 FR 68434) [s1]. The 2016 revised draft covered when an ingredient is an NDI, when the notification requirement applies, what safety data to consider, what to include in a notification, and how to submit one.

Rather than finalise the entire 2016 draft at once, the FDA has carved out the identity and safety portions into a stand-alone document. The final guidance "finalizes in a stand-alone document the identity and safety recommendations" that had appeared in sections VI.A, VI.B and VI.C of the 2016 draft — covering identity information about the NDI and the dietary supplement, history of use or other evidence of safety, and the summary of the basis for a safety conclusion [s1]. The FDA says it has also updated the 2016 revised draft to mark which portions are now final and which remain in draft, leaving the rest of that document in place [s2].

From 'safety profile' to 'safety narrative'

The substantive change is one of format. To "alleviate the burden of submitting separate documents regarding the safety data submitted in an NDIN," the agency has eliminated references to a "comprehensive safety profile" and instead recommends the use of a single "safety narrative" for all notifications [s1]. In plain terms, companies would compile their safety evidence into one structured account rather than assembling several separate submissions.

The FDA says it made changes "to provide additional clarity and description regarding what should be included in the NDIN safety narrative, when additional evidence of safety should be submitted, and what types of studies are recommended to support an NDIN," along with editorial changes to improve clarity [s1]. The agency frames the revision as consolidation and clarification rather than a new substantive standard.

What the guidance does and does not do

Guidance documents are not regulations. The FDA issued this one under its good guidance practices regulation at 21 CFR 10.115, and states that it "represents our current thinking on this topic," that it "does not establish any rights for any person and is not binding on FDA or the public," and that a company may use an alternative approach that satisfies the applicable statutes and regulations [s1]. The underlying notification requirement itself sits in FDA regulation at 21 CFR 190.6; the information-collection provisions in the guidance are approved under the Office of Management and Budget control number 0910-0330 [s1].

Because the guidance is final, companies preparing an NDIN now have a settled description of the identity and safety information the FDA expects — including the single safety-narrative format — even as other parts of the broader 2016 draft remain unfinished. The FDA considered Executive Order 14192 and found the action to be neither a regulatory nor a deregulatory action under that order [s1], a further signal that the agency regards the change as a clarification of existing practice rather than a new burden or a rollback.

For supplement makers, the practical effect is procedural: a clearer, consolidated template for the safety case that must accompany a new ingredient. For consumers, the premarket safety review that notifications are meant to support is unchanged in substance; what has changed is how the evidence behind it is organised and presented to the agency.